Hims & Hers Health, Inc. (BCBA:HIMS)
Argentina · Delayed Price · Currency is ARS | Market Cap | 11.28T -20.2% |
| Revenue (ttm) | 3.27T +32.8% |
| Net Income | -18.28B |
| EPS | -80.71 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 38.33 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 124,171 |
| Open | 13,200 |
| Previous Close | 12,990 |
| Day's Range | 11,200 - 13,680 |
| 52-Week Range | 8,035 - 15,300 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 10, 2026 |
About Hims & Hers Health
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and de... [Read more]
Financial Performance
In 2025, Hims & Hers Health's revenue was $2.35 billion, an increase of 59.00% compared to the previous year's $1.48 billion. Earnings were $128.37 million, an increase of 1.85%.
Financial numbers in USD Financial StatementsNews
Is Today’s Dip a Buying Opportunity for Hims & Hers Health (HIMS) Stock?
Hims & Hers Health stock fell hard on Friday and investors might be wondering if now is the time to buy the shares.
Hims & Hers falls -10.3%
Hims & Hers (HIMS) is down -10.3%, or -$3.38 to $29.36.
Canaccord Expects Hims & Hers Stock (HIMS) to Outperform ‘Major Indices by Several Hundred Basis Points.’ Here’s Why
Hims & Hers Health ($HIMS) stock rose 3.4% on Thursday after the Pharmacy Compounding Advisory Committee (PCAC) of the U.S. Food and Drug Administration (FDA) voted to place BPC-157, a widely…
Here’s Why Hims & Hers Stock Soared 13% Today – July 23, 2026
Hims & Hers Health ($HIMS) surged as much as 13% on Thursday after the Food and Drug Administration (FDA) advisory panel voted to recommend loosening restrictions on a popular peptide…
Hims & Hers stands to gain if the FDA loosens restrictions on peptides
Hims & Hers Health is set to tap what analysts estimate could be a multi-billion-dollar market for peptides if U.S. regulators loosen manufacturing restrictions.
Hims & Hers Chief Accounting Officer, Irene Becklund, Announces Departure from the Company
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced its Chief Accounting Officer, Irene Becklund will depart the company af...
Hims & Hers to Announce Second Quarter 2026 Financial Results on August 10, 2026
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report second quarter 2026 financial result...
Hims & Hers (HIMS) Stock Still Has Upside, but Risks Persist
Hims & Hers Health ($HIMS) still has significant upside potential, but the risks are equally real. That is what makes the stock one of the more interesting high-risk, high-reward names…
Amplify Online Retail ETF Rides a Summer Surge in Performance
The Amplify Online Retail ETF (IBUY) has rallied over the past month, signaling a robust appetite for online consumer discretionary spending despite persistent macroeconomic headwinds. Outsized gains ...
Hims & Hers stock jumps as Canaccord lifts target price ahead of FDA review
Hims & Hers Health shares (HIMS) surged 9% on Wednesday after Canaccord Genuity raised its price target on the telehealth company, citing improving sales trends, momentum in its weight-loss business, ...
HIMS Stock Rallies after Canaccord Raises Price Target to Street-High of $40
Shares of Hims & Hers ($HIMS) are up 5.4% in regular trading after receiving a new Street-high price target of $40. Canaccord Genuity analyst Maria Ripps maintained her Buy rating…
Hims' obesity drug business may get boost as employers drop coverage
Telehealth provider Hims and Hers Health may get a boost next year from employers dropping coverage of weight-loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound and Foundayo to rein in co...
Living Longer Is Big Business. These Stocks Will Benefit.
TD Cowen analysts estimate that the total addressable market for longevity healthcare exceeds $250 billion.
Hims & Hers Health Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and executive compensation, all of which were approved by majority or plurality vote. Stockholders could submit questions virtually, with responses to follow after the meeting.
Hims & Hers Names Dr. Anant Vinjamoori as Chief Medical Officer of Hims
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced Dr. Anant Vinjamoori is joining as the Chief Medical Officer of the Him...
Hims & Hers Health Transcript: 2026 Evercore Global TMT Conference
Ambitious 2030 targets are set, driven by global expansion, specialty growth, and technology investments. Recent acquisitions and partnerships, especially with Eucalyptus and Novo Nordisk, accelerate international reach and deepen consumer engagement. AI and data are central to platform differentiation and operational efficiency.
Hims & Hers Completes Acquisition of Eucalyptus, Accelerating Its Push to Transform Healthcare for Canadians
TORONTO--(BUSINESS WIRE)--Hims & Hers Health, Inc. today announced the completion of its acquisition of Eucalyptus, the parent company of Juniper, marking the latest in a series of significant company...
Hims & Hers Completes Acquisition of Eucalyptus, Advancing its Position as the World's Largest Consumer Health Platform
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) has completed its acquisition of Eucalyptus, advancing its position as the world's largest consumer health platform. Building on t...
Hims & Hers Completes Acquisition of Eucalyptus, Expanding Access to Comprehensive, Clinically-Backed Weight Management Care in Germany
BERLIN--(BUSINESS WIRE)--Hims & Hers Health, Inc. has completed its acquisition of Eucalyptus, the parent company of Juniper, advancing its position as the world's largest consumer health platform. In...
Hims & Hers Completes Acquisition of Eucalyptus, Advancing Position as the World's Largest Consumer Health Platform
SYDNEY--(BUSINESS WIRE)--Hims & Hers Health, Inc. has completed its acquisition of Eucalyptus – the parent company of Juniper, Pilot, Kin, and Software – advancing its position as the world's largest ...
Hims & Hers Completes Acquisition of Eucalyptus, Parent Company of Juniper, Officially Entering Japanese Market
TOKYO--(BUSINESS WIRE)--Hims & Hers Health, Inc. has completed its acquisition of Eucalyptus, the parent company of Juniper, marking a significant milestone in the company's global growth and its form...
Hims & Hers Expands Benefits for Active Subscribers With Eight New Health and Wellness Partners
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the expansion of Hims & Hers Benefits, adding eight new partners to the...
Hims & Hers Health Slides: Investor presentation
Hims & Hers Health has posted slides in relation to its latest quarterly earnings report, which was published on May 28, 2026.
Hims offers Apotex's generic semaglutide in Canada after Novo patent expiry
Hims & Hers Health said on Thursday it is now offering Canadians with type 2 diabetes a generic version of semaglutide, the active ingredient in Novo Nordisk's blockbuster drug Ozempic, through its ...
Hims & Hers Expands GLP-1 Offering in Canada with Generic Semaglutide
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform in Canada....